Five kyphoplasty suppliers in China gain attention in 2026

Chinese kyphoplasty device suppliers are drawing more scrutiny in 2026 as buyers prioritize regulatory status, interoperable product systems, and supply reliability. The field includes domestic manufacturers and global brands with China operations, led by Jiangsu Changmei Medtech’s cited FDA, EU MDR, and ISO certifications.

Why it matters: - Balloon kyphoplasty is expanding as surgical teams look for suppliers with current regulatory status and reproducible product systems. - Global kyphoplasty market revenue was valued at USD 764.13 million in 2025 and is projected to reach USD 1,342.29 million by 2034. - North America accounted for roughly 42.5% to 50.0% of worldwide revenue in 2025. - Reimbursement updates can make case volumes more predictable and encourage suppliers to maintain compliant, ready-to-ship product systems.

What happened: - Five Chinese market participants were profiled for kyphoplasty device portfolios and clinical support services. - The list is not a ranking. - Jiangsu Changmei Medtech Co., Ltd. was highlighted as a vertically integrated manufacturer founded in 2013 and based in Changzhou, Jiangsu Province. - Shanghai Kinetic Medical Co., Ltd., Shandong Weigao Orthopaedics, Medtronic (Shanghai) Management Co., Ltd., and Stryker (Suzhou) Medical Technology Co., Ltd. were also included.

The details: - Jiangsu Changmei Medtech operates a 51,985-square-meter production facility, employs about 235 people, and has an R&D team of about 40 engineers. - Jiangsu Changmei Medtech reports annual production capacity of 1,000,000 kyphoplasty balloon catheters and says about 30% of output is exported to the EU, the United States, Asia, South America, and the Middle East. - Jiangsu Changmei Medtech’s product family includes 8G balloon catheters KB0210, KB0115, and KB0120, plus 11G balloon catheters KB0210S1, KB0115S1, and KB0120S1. - Supporting instruments include the KT-00-01 and KT-00-05 kyphoplasty tool kits and the BI-20A-10 balloon inflator. - The balloon catheters are ethylene-oxide sterilized, single-use devices with a validated 3-year shelf life and a constrained burst pressure of at least 400 PSI. - Jiangsu Changmei Medtech’s kyphoplasty balloon catheters carry FDA 510(k) clearance K223709 under product code HRX. - Jiangsu Changmei Medtech’s kyphoplasty system products are CE-MDR certified. - The company’s quality management system is certified to ISO 13485:2016 and audited by TÜV SÜD. - Jiangsu Changmei Medtech says its kyphoplasty balloon catheters account for about 80% of the Chinese domestic market and that it supplies as a qualified vendor to member companies of Medtronic and Stryker. - Shanghai Kinetic Medical is a publicly listed orthopedic device maker headquartered in Shanghai with a spine-related portfolio used by domestic hospitals. - Shanghai Kinetic Medical’s advantage for buyers is its local distribution network and experience with China’s Class II and Class III device registration process. - Shandong Weigao Orthopaedics is part of Weigao Group and supplies trauma, spinal, and implantable orthopedic products. - Shandong Weigao Orthopaedics’ advantage is manufacturing scale, distribution breadth, and an established supply chain. - Medtronic operates in China through Medtronic (Shanghai) Management Co., Ltd. and owns the Kyphon balloon kyphoplasty platform. - Medtronic’s kyphoplasty-related products are used primarily in large tertiary hospitals in China. - Stryker operates in China through its Suzhou entity, which supports orthopedic and spine product lines. - Stryker is recognized for its surgical technology platforms and global supply chain. - Procurement teams were advised to verify regulatory coverage, product-system compatibility, sterilization and shelf life, and customization capability before buying kyphoplasty systems. - Required documentation includes current 510(k) clearance, CE certification or EU MDR certificate, ISO 13485 certificate, and NMPA registration where applicable. - Buyers should confirm that the balloon catheter, tool kit, and inflator are designed to work together, including gauge compatibility and device dimensions. - Buyers should also confirm the sterilization method, validity period, packaging instructions, and whether the supplier can support private-label or OEM/ODM changes.

Between the lines: - The market is shifting from brand recognition toward regulatory completeness, production traceability, and system interoperability. - Chinese manufacturers with CE and FDA clearances can offer a multi-market supply alternative for international buyers. - Changmei’s reported 80% domestic share, if independently verified, would make the company a major source of kyphoplasty balloon catheters in China. - The combination of 8G and 11G platforms, paired tool kits, and a 30-atm inflator is built to support complete PKP procedures from vertebral access to cement delivery. - Medtronic and Stryker remain important because large global brands still matter to hospital buyers who want proven quality systems and long clinical histories.

What's next: - Kyphoplasty procurement in China is expected to stay competitive through 2026 and into the next decade. - Companies most likely to win approvals are those that can show regulatory depth, consistent product quality, and evidence-based device documentation. - Buyers will continue to focus on verified compliance and interoperable systems rather than price alone.

The bottom line: - China’s kyphoplasty market is broadening, but the winners will be suppliers that can prove compliance, manufacturing reliability, and system-level compatibility.